Will new antimicrobials overcome resistance among Gram-negatives?

References

• Kallen AJ, Srinivasan A. Current epidemiology of multidrug-resistant Gram-negative bacilli in the United States. Infect. Control Hosp. Epidemiol.31(Suppl. 1), S51–S54 (2010).
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill.13, pii: 19045 (2008).
   Google Scholar
• Rodloff AC, Leclercq R, Debbia EA, Canton R, Oppenheim BA, Dowzicky MJ. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin. Microbiol. Infect.14(4), 307–314 (2008).
   PubMed Web of Science ®Google Scholar
• Maragakis LL. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit. Care Med, 38(Suppl. 8), S345–S351 (2010).
   PubMed Web of Science ®Google Scholar
• Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clin. Infect. Dis.49(6), 992–993 (2009).
   PubMed Web of Science ®Google Scholar
• Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob. Agents Chemother.52(3), 813–821 (2008).
   PubMed Web of Science ®Google Scholar
• Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother.66(1), 1–14 (2010).
   PubMed Web of Science ®Google Scholar
• Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against Gram-negative bacteria collected in the United States. Clin. Ther.32(4), 766–779 (2010).
   PubMedGoogle Scholar
• Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis.46(2), 155–164 (2008).
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America. The 10 × ‘20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis.50(8), 1081–1083 (2010).
   PubMed Web of Science ®Google Scholar
• Schaack S, Gilbert C, Feschotte C. Promiscuous DNA: horizontal transfer of transposable elements and why it matters for eukaryotic evolution. Trends Ecol. Evol.25(9), 537–546 (2010).
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Quinn JP. The spread of Klebsiella pneumoniae carbapenemases: a tale of strains, plasmids, and transposons. Clin. Infect. Dis.49(11), 1739–1741 (2009).
   PubMedGoogle Scholar
• Brakhage AA, Al-Abdallah Q, Tüncher A, Spröte P. Evolution of β-lactam biosynthesis genes and recruitment of trans-acting factors. Phytochemistry66(11), 1200–1210 (2005).
   PubMedGoogle Scholar
• Rawat D, Nair D. Extended-spectrum β-lactamases in Gram negative bacteria. J. Glob Infect. Dis.2(3), 263–274 (2010).
   PubMedGoogle Scholar
• Walsh TR. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents.36(Suppl. 3), S8–S14 (2010).
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother.60(5), 913–920 (2007).
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother.39(6), 1211–1233 (1995).
   PubMed Web of Science ®Google Scholar
• Ambler RP. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci.289(1036), 321–331 (1980).
   PubMed Web of Science ®Google Scholar
• Thomson KS. Extended-spectrum-β-lactamase, AmpC, and carbapenemase issues. J. Clin. Microbiol.48(4), 1019–1025 (2010).
   PubMed Web of Science ®Google Scholar
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis.9(4), 228–236 (2009).
   PubMed Web of Science ®Google Scholar
• Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis.10(9), 597–602 (2010).
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L, Toleman MA et al. Does broad-spectrum β-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J. Antimicrob. Chemother.66(4), 689–692 (2011).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist. Update13(4–5), 132–138 (2010).
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N. Engl. J. Med.358(12), 1271–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev.22(4), 582–610 (2009).
   PubMed Web of Science ®Google Scholar
• Poulakou G, Kontopidou FV, Paramythiotou E et al. Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens. J. Infect.58(4), 273–284 (2009).
   PubMed Web of Science ®Google Scholar
• Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb. Drug Resist.13(1), 1–6 (2007).
   PubMed Web of Science ®Google Scholar
• Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem.3(3), 249–282 (2003).
   PubMed Web of Science ®Google Scholar
• Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria – a description of the action, resistance mechanism, and nosocomial battleground. J. Biomed. Sci.15(1), 5–14 (2008).
   PubMed Web of Science ®Google Scholar
• Dozzo P, Moser HE. New aminoglycoside antibiotics. Expert Opin. Ther. Pat.20(10), 1321–1341 (2008).
   Google Scholar
• Eschenburg S, Priestman M, Schonbrunn E. Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamineenolpyruvyltransferase (MurA) is essential for product release. J. Biol. Chem.280(5), 3757–3763 (2005).
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Kuzuyama T, Seto H. Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli. Antimicrob. Agents Chemother.44(3), 647–650 (2010).
   Google Scholar
• Bassetti M, Righi E, Viscoli C. Novel β-lactam antibiotics and inhibitor combinations. Expert Opin. Investig. Drugs.17(3), 285–296 (2008).
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis.46(5), 647–655 (2008).
   PubMed Web of Science ®Google Scholar
• El Solh A. Ceftobiprole: a new broad spectrum cephalosporin. Expert Opin. Pharmacother.10(10), 1675–1686 (2009).
   PubMed Web of Science ®Google Scholar
• Nannini EC, Stryjewski ME, Corey GR. Ceftaroline for complicated skin and skin-structure infections. Expert Opin. Pharmacother.11(7), 1197–1206 (2010).
   PubMed Web of Science ®Google Scholar
• Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother.53(6), 2360–2366 (2009).
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis.51(6), 641–650 (2010).
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother.60(2), 300–311 (2007).
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG. In vitro Activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob. Agents Chemother.55(6), 2837–2846 (2011).
   PubMed Web of Science ®Google Scholar
• Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother.54(3), 1213–1217 (2010).
   PubMed Web of Science ®Google Scholar
• Brown NP, Pillar CM, Sahm DF, Alluru V, Grover P, Ge Y. Activity profile of CXA-101 and CXA-101/tazobactam against target Gram-positive and Gram-negative pathogens. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Ge Y, Whitehouse MJ, Friedland I, Talbot GH. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob. Agents Chemother.54(8), 3427–3431 (2010).
   PubMed Web of Science ®Google Scholar
• Titelman E, Karlsson IM, Ge Y, Giske CG. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis.70(1), 137–141 (2011).
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement (June 2010 Update) M100-S20-U. CLSI, Wayne, PA, USA (2010).
   Google Scholar
• Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. Current status of newer carbapenems. Curr. Med. Chem.16(5), 564–575 (2009).
   PubMed Web of Science ®Google Scholar
• Chahine EB, Ferrill MJ, Poulakos MN. Doripenem: a new carbapenem antibiotic. Am. J. Health Syst. Pharm.67(23), 2015–2024 (2010).
   PubMed Web of Science ®Google Scholar
• Betriu C, Gomez M, Lopez-Fabal F, Culebras E, Rodríguez-Avial I, Picazo JJ. Activity of doripenem against extended-spectrum β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates. Eur. J. Clin. Microbiol. Infect. Dis.29(9), 1179–1181 (2010).
   PubMed Web of Science ®Google Scholar
• Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob. Agents Chemother.54(1), 565–569 (2010).
   PubMedGoogle Scholar
• Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med.36(4), 1089–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Jia B, Lu P, Huang W et al. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy56(4), 285–290 (2010).
   PubMed Web of Science ®Google Scholar
• Gomi K, Fujimura S, Fuse K et al. Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007. J. Infect. Chemother.17(2), 200–206 (2011).
   PubMed Web of Science ®Google Scholar
• Fukushima Y, Fukushima F, Kamiya K et al. Relation between the antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from respiratory specimens and antimicrobial use density (AUD) from 2005 through 2008. Intern. Med.49(14), 1333–1340 (2010).
   PubMedGoogle Scholar
• Fujimura S, Nakano Y, Sato T, Shirahata K, Watanabe A. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa. J. Infect. Chemother.13(3), 147–150 (2007).
   PubMed Web of Science ®Google Scholar
• Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T. Potent In vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother.52(8), 2849–2854 (2008).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M. Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J. Antimicrob. Chemother.64(2), 330–335 (2009).
   PubMed Web of Science ®Google Scholar
• Goa KL, Noble S. Panipenem/betamipron. Drugs63(9), 913–925, discussion 926 (2003).
   PubMedGoogle Scholar
• Yoshida S, Koga T, Kakuta M et al.In-vitro activity of panipenem against clinical isolates in 2006. Jpn J. Antibiot.61(1), 1–17 (2008).
   PubMedGoogle Scholar
• Morrissey I, Biek D, Janes R. ME1036, a novel carbapenem, with enhanced activity against clinical isolates causing bacteraemic community-acquired pneumonia. J. Antimicrob. Chemother.64(1), 209–210 (2009).
   PubMedGoogle Scholar
• Russo TA, Page MG, Beanan JM et al.In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J. Antimicrob. Chemother.66(4), 867–873 (2011).
   PubMed Web of Science ®Google Scholar
• Page MG, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob. Agents Chemother.54(6), 2291–2302 (2010).
   PubMed Web of Science ®Google Scholar
• Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int. J. Med. Microbiol.300(6), 371–379 (2010).
   PubMed Web of Science ®Google Scholar
• Weiss WJ, Petersen PJ, Murphy TM et al.In vitro and in vivo activities of novel 6-methylidene penems as β-lactamase inhibitors. Antimicrob. Agents Chemother.48(12), 4589–4596 (2004).
   PubMed Web of Science ®Google Scholar
• Bebrone C, Lassaux P, Vercheval L et al. Current challenges in antimicrobial chemotherapy: focus on β-lactamase inhibition. Drugs70(6), 651–679 (2010).
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jones CH, Venkatesan AM, Bradford PA. Efficacy of piperacillin combined with the penem β-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob. Agents Chemother.53(4), 1698–1700 (2009).
   PubMed Web of Science ®Google Scholar
• Shahid M, Sobia F, Singh A et al. β-lactams and β-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update. Crit. Rev. Microbiol.35(2), 81–108 (2009).
   PubMed Web of Science ®Google Scholar
• Ruzin A, Petersen PJ, Jones CH. Resistance development profiling of piperacillin in combination with the novel {β}-lactamase inhibitor BLI-489. J. Antimicrob. Chemother.65(2), 252–257 (2010).
   PubMed Web of Science ®Google Scholar
• Paukner S, Hesse L, Prezelj A, Solmajer T, Urleb U. In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {β}-lactamase inhibitor. Antimicrob. Agents Chemother.53(2), 505–511 (2009).
   PubMed Web of Science ®Google Scholar
• Jamieson CE, Lambert PA, Simpson IN. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother.47(8), 2615–2618 (2003).
   PubMed Web of Science ®Google Scholar
• Bowker KE, Noel AR, Walsh TR, Rogers CA, MacGowan AP. Pharmacodynamics of ceftazidime plus the serine β-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 β-lactamases. Antimicrob. Agents Chemother.48(11), 4482–4484 (2004).
   PubMed Web of Science ®Google Scholar
• Lagacé-Wiens PR, Tailor F, Simner P et al. Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. Antimicrob. Agents Chemother.55(5), 2434–2437 (2011).
   PubMed Web of Science ®Google Scholar
• Curcio D. Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104. Expert Rev. Anti Infect. Ther.9(2), 173–176 (2011).
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother.65(7), 1428–1432 (2010).
   PubMed Web of Science ®Google Scholar
• Melchers R, Mavridou E, Van Mil A, Motyl MR, Mouton JW. In vitro activity of imipenem alone and in combination with MK-7655: a new β-lactamase inhibitor. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Mavridou E, Melchers R, Van Mil A, Mangin E, Mouton JW. Pharmacodynamics of imipenem in combination with MK-7655, a β-lactamase inhibitor, in the neutropenic mouse thigh model. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Hirsch EB, Ledesma KR, Chang KT, Motyl MR, Tam VH. In vitro activity of MK-7655 in combination with imipenem (IPM) against carbapenem resistant Gram-negative bacteria. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Maltezou HC. Metallo-β-lactamases in Gram-negative bacteria: introducing the era of pan-resistance? Int. J. Antimicrob. Agents.33(5), 405, e1–e7 (2009).
   PubMedGoogle Scholar
• Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J. Antimicrob. Chemother.65(11), 2382–2395 (2010).
   PubMed Web of Science ®Google Scholar
• Page MG, Dantier C, Desarbre E, Gaucher B, Gebhardt K, Schmitt-Hoffmann A. In vitro and in vivo properties of BAL30376, a β-lactam and dual β-lactamase inhibitor combination with enhanced activity against Gram-negative bacilli that express multiple β-lactamases. Antimicrob. Agents Chemother.55(4), 1510–1519 (2011).
   PubMed Web of Science ®Google Scholar
• Ishii Y, Eto M, Mano Y, Tateda K, Yamaguchi K. In vitro potentiation of carbapenems with ME1071, a novel metallo-β-lactamase inhibitor, against metallo-β-lactamase- producing Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother.54(9), 3625–3629 (2010).
   PubMed Web of Science ®Google Scholar
• Sutcliffe J, Ronn M, Leighton A, Sprenger C. Phase 1 single ascending dose study of a broad-spectrum fluorocycline, TP-434. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Talbot GH. The antibiotic development pipeline for multidrug-resistant Gram-negative bacilli: current and future landscapes. Infect. Control Hosp. Epidemiol.31(Suppl. 1), S55–S58 (2010).
   Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother.66(1), 48–53 (2011).
   PubMed Web of Science ®Google Scholar
• Landman D, Kelly P, Bäcker M et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J. Antimicrob. Chemother.66(2), 332–334 (2011).
   PubMed Web of Science ®Google Scholar
• Landman D, Babu E, Shah N et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J. Antimicrob. Chemother.65(10), 2123–2127 (2011).
   Google Scholar
• Sader HS, Rhomberg PR, Jones RN. Antimicrobial activity of a novel polymyxin analog (CB-182,804) tested against clinical strains of Gram-negative bacilli, including colistin-resistant organisms. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Opperman TJ, Houseweart C, Williams JD, Peet NP, Moir DT, Bowlin TL. The mechanism of antibacterial action of novel bis-indole antibiotics. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Butler MM, Williams JD, Peet NP et al. Comparative in vitro activity profiles of novel bis-indole antibacterials against Gram-positive and Gram-negative clinical isolates. Antimicrob. Agents Chemother.54(9), 3974–3977 (2010).
   PubMedGoogle Scholar
• Hernandez V, Akama T, Alley M et al. Discovery and mechanism of action of AN3365: a novel boron containing antibacterial agent in clinical development for Gram-negative infections. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Biedenbach DJ, Mendes RE, Alley MRK, Sader HS, Jones R. Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against non-fermentative Gram-negative bacilli. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Bouchillon S, Hoban D, Hackel M, Butler D, Demarsch P, Alley D. In vitro activities of AN3365: a novel boron containing protein synthesis inhibitor and other antimicrobial agents against anaerobes and Neisseria gonorrhoeae. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Freund YR, Liu L, Alley MRK et al. Murine pharmacokinetics and in vivo Gram-negative activity of AN3365: a novel boron-containing protein synthesis inhibitor. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Mansoor UF, Vitharana D. Reddy PA et al. Design and synthesis of potent Gram-negative specific LpxC inhibitors. Bioorg Med. Chem. Lett.21(4), 1155–1161 (2011).
   PubMed Web of Science ®Google Scholar
• Ippolito J, Wang D, Chen S et al. Novel antibiotic classes to treat Gram-negative infections. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Peters BM, Shirtliff ME, Jabra-Rizk MA. Antimicrobial peptides: primeval molecules or future drugs? PloS Pathog.6(10), e1001067 (2010).
   PubMed Web of Science ®Google Scholar
• Vila-Farres X, Garcia-De La Maria C, Giralt E, Vila J. In vitro activity of mastoparan against colistin-susceptible and resistant Acinetobacter baumannii. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Baer M, Sawa T, Flynn P et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun.77(3), 1083–1090 (2009).
   PubMed Web of Science ®Google Scholar
• Page MG, Heim J. Prospects for the next anti-Pseudomonas drug. Curr. Opin. Pharmacol.9(5), 558–565 (2009).
   PubMed Web of Science ®Google Scholar